We believe that our R&D business has tremendous potential for growth and long-term profitability.
Earlier in April, Sun Pharmaceuticals Industries announced acquisition of Ranbaxy in an all-share deal.
Mukesh Ambani continues to remain the richest man in India.
Sun Pharmaceutical Industries Ltd has entered into an agreement with two large shareholders of its subsidiary Caraco Pharmaceutical Laboratories Ltd to acquire most of their common stock and options in the latter for $42 million.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
Researchers at Northwell Health in New York are testing the effects on Famotidine (used in high intravenous doses) on Covid-19 patients as a potential treatment. After the hospital announced its clinical trials, it led to a drug shortage in the US. Back home, however, there has not been any surge in the demand for Famotidine yet.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Sun Pharmaceutical's acquisition of Ranbaxy has received final approvals.
Sun Pharmaceuticals Industries Ltd has posted a 45.01 per cent rise in its consolidated net profit at Rs 358.9 crore (Rs 3.59 billion) for the financial year 2003-04 as against Rs 247.5 crore (Rs 2.47 billion) in 2002-03.
From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.
Experts said the 20 per cent drop in the market poses a challenge for companies that have set the ball rolling on their IPO plans as valuations will now have to realign. This could entail more dilution or lowering of the issue size.
Earning woes drag markets lower; TCS, HUL lead fall.
People close to Shanghvi reveal he is known to make surprising moves both inside and outside the pharma industry.
While the UN report said that FDI inflows rose 6 per cent in 2018 to $ 42 billion, the government's own data for the entire FY19 period has shown that inbound equity investments declined for the first time in six years in FY19.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
The recent recalls come amid increased FDA scrutiny of medicines produced in India.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
Sun Pharma stated the company wanted shareholders' approval to "issue, offer and allot equity shares or non-convertible securities, other than warrants, up to an amount of Rs 12,000 crore ($2 billion), to qualified institutional buyers pursuant to a QIP."
'When you have surplus cash flow and markets correct sharply, what options do you have other than buying good stocks?'
Nearly 150 senior management staff will be asked to leave.
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
IT major TCS worst hit; it's m-cap slumped by Rs 11,811.13 cr to Rs 4,92,042.26 cr
India seeks greater market access for its products including textiles, pharmaceuticals and bovine meat.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
In the ranking of top-10 firms, TCS stood at number one position
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances